340B is a lifesaving program that costs taxpayers nothing, and is constantly under attack from politicians, lobbyists and Big Pharma

JOIN US and get involved. We all have the power to tell Congress to Let it B!

JOIN THE FIGHT

Don’t let pharmaceutical companies win!

This rule would block millions of patients from care.

It’s time to tell Congress to
Let it B.


Call your member of Congress at (202) 224-3121

Click to Help Save 340B

What 340b Does For Patients


For the past 25 years, 340B has helped provide low-cost medications and better health outcomes for millions of Americans and the non-profit clinics and hospitals who serve them.

340B savings enable safety net providers to fund services and care for uninsured and underinsured patients.


  • 340B Benefits Patients & Safety-Net Providers

  • It Costs the Taxpayers & Government Nothing

  • Greedy Drug Companies Oppose It

  • Leave it Alone. It isn't Broken.

It’s time to tell Congress to
Let it B.


Call your member of Congress at (202) 224-3121

Click to Help Save 340B

340b Updates


Yesterday Let 340B marched to #protect340b in front of Sponsor of H.R. 4710, Rep. Larry Bucshon’s district office.
Hey greedy politicians and Pharma execs: HANDS OFF 340B! | #let340b | #letitb | #340b

Our elected officials need to understand the value of this 25 year old program and continue to support 340B!

JOIN US and get involved.
We all have the power to tell Congress to Let it B!

call your congress member now

Learn The Facts


MYTH:

The continuing growth in the 340B program is not sustainable.

FACT:

A condition of Pharma gaining access to the $33.4 billion Medicaid drug market is that they agree to participate in the 340B program. As long as pharma wants access to that $33.4 billion market, they will participate in the 340B program, which will continue well into the future.

MYTH:

340B has experienced out of control, exponential expansion.

FACT:

Congress intentionally expanded the program, with the full knowledge and tacit approval of the drug industry. In 2010, as part of the Aordable Care Act, Congress increased the number and types of nonprofit hospitals that can participate. The growth in the 340B program was intended, and was completely expected. The drug companies actively pushed for ACA because they knew that, between Medicaid expansion and the individual mandate, they would have a payer source for their drugs for tens of millions of new people. They have made out like bandits: Since 2010, Medicaid drug sales have now increased by $13 billion per year Since 2010, total drug company sales have now increased by over $85 billion per year By contrast, 340B discounts have grown by a much more modest amount. While total 340B sales have increased, the discounts oered on those 340B drugs (i.e., the amount that Covered Entities would have paid in the absence of the 340B Program) was far less than pharma asserts. In 2015, the total discounts for 340B drugs increased by only $2 billion from 2010. Largely due to ACA, pharma gets an extra $85 billion per year, and gives up very little. And now they want to renege on that!

MYTH:

340B is incentivizing industry consolidation, driving up prices.

FACT:

While the health care industry is consolidating, it is consolidating everywhere, even in places without 340B (think the merger of CVS and Aetna). While pharma likes to use hospital purchases of oncology practices as its prime example, hospital/oncology acquisitions with 340B are occurring at the same rate as hospital/oncology practices without 340B.

MYTH:

Congress did not clearly identify the intent of the 340B program, thereby allowing nonprofit entities to abuse it.

FACT:

The intent of the 340B program is stated quite clearly in its legislative history. The purpose of 340B is to give safety net providers relief from high drug prices, so they have the resources to provide more and better services to their clients: In giving these ‘covered entities’ access to price reductions the committee intends to enable these entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. Further, the 340B law clearly anticipates that prescriptions could and would be reimbursed by insurers like Medicaid, because there is specific language dealing with how 340B entities should bill Medicaid.


340B discounts totaled $6 billion in 2015, thats 1.3 percent of total US drug sales in that year. Thats it.

The COST to taxpayers: Zero. The 340B Program simply allows eligible health care providers that serve a large number of low-income patients to purchase medications at a special discount from drug makers. That savings can, in turn, be used by these eligible providers to fund services and care for their patients, and at no cost to taxpayers.

Since 1992, the 340B Program has allowed safety net providers serving low income communities to use prescription drug savings obtained directly from drug manufacturers to fund more services to more patients.

Downloadable Resources


Write to your Representative

Write to your Senator

Click the images to Share to Facebook


340B
A small program that
does a world of good.

In the Headlines: The Latest News on 340B



No Cost to
the Taxpayers

Your voice is needed! Thank you for your interest in joining the fight to SAVE 340B!

Complete this form and we will add your name ONLY to the message list that we’ll be sending to your local State Senator and/or Representative. We will also keep you updated on ways to lend your voice and get involved.
















Writing a letterCalling congressDemonstratingLeading a volunteer groupVolunteering


YesNo

YesNo

Call your local HELP Committee Member and demand to Let 340B!


Patty Murray (WA) (202) 224-2621

Bernie Sanders (VT) (202) 224-5141

Robert P. Casey, Jr (PA) (202) 224-6324

Michael F. Bennet (CO) 202-224-5852

Tammy Baldwin (WI) (202) 224-5653

Christopher S. Murphy (CT) (202) 224-4041

Elizabeth Warren (MA) (202) 224-4543

Tim Kaine (VA) (202) 224-4024

Maggie  Hassan (NH) (202) 224-3324

Tina Smith (MN) (202) 224-5641

Doug Jones (AL) (202) 224-4124

Lamar Alexander (TN) (202) 224-4944

Michael B. Enzi (WY) (202) 224-3424

Richard Burr (NC) (202) 224-3154

Johnny Isakson (GA) (202) 224-3643

Rand Paul (KY) (202) 224-4343

Susan Collins (ME) (202) 224-2523

Bill Cassidy, M.D. (LA) (202) 224-5824

Todd Young (IN) (202) 224-5623

Orrin  Hatch (UT) (202) 224-5251

Pat Roberts (KS) (202) 224-4774

Lisa Murkowski (AK) (202)-224-6665

Tim Scott (SC) (202) 224-6121